Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

…, P Morgan, G Satterthwaite, MN Pangalos - Nature reviews Drug …, 2014 - nature.com
Maintaining research and development (R&D) productivity at a sustainable level is one of the
main challenges currently facing the pharmaceutical industry. In this article, we discuss the …

Impact of a five-dimensional framework on R&D productivity at AstraZeneca

…, S Platz, S Rees, MA Snowden, MN Pangalos - Nature reviews Drug …, 2018 - nature.com
In 2011, AstraZeneca embarked on a major revision of its research and development (R&D)
strategy with the aim of improving R&D productivity, which was below industry averages in …

[HTML][HTML] Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine

…, T Takas, RP Marshall, MN Pangalos… - … England Journal of …, 2021 - Mass Medical Soc
Background The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large,
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (…

Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease

…, JH Morrison, MN Pangalos… - Proceedings of the …, 2006 - National Acad Sciences
Alzheimer's disease (AD) is a progressive neurodegenerative disorder for which numerous
mouse models have been generated. In both AD patients and mouse models, there is …

Activation of estrogen receptor-β regulates hippocampal synaptic plasticity and improves memory

…, PH Reinhart, KL Marquis, SJ Moss, MN Pangalos… - Nature …, 2008 - nature.com
Estrogens have long been implicated in influencing cognitive processes, yet the molecular
mechanisms underlying these effects and the roles of the estrogen receptors alpha (ERα) and …

Drug development for CNS disorders: strategies for balancing risk and reducing attrition

MN Pangalos, LE Schechter, O Hurko - Nature Reviews Drug Discovery, 2007 - nature.com
Disorders of the central nervous system (CNS) are some of the most prevalent, devastating
and yet poorly treated illnesses. The development of new therapies for CNS disorders such …

[HTML][HTML] Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of Covid-19

…, A Sharbaugh, K Streicher, MN Pangalos… - … England Journal of …, 2022 - Mass Medical Soc
Background The monoclonal-antibody combination AZD7442 is composed of tixagevimab
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …

Rapamycin alleviates toxicity of different aggregate-prone proteins

…, LG Oroz, BR Underwood, MN Pangalos… - Human molecular …, 2006 - academic.oup.com
Many neurodegenerative diseases are caused by intracellular, aggregate-prone proteins,
including polyglutamine-expanded huntingtin in Huntington's disease (HD) and mutant tau in …

The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans

…, H Bright, NL Kallewaard, MN Pangalos… - Science translational …, 2022 - science.org
Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines, there remains a need for more prevention and treatment options for individuals …

Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double …

…, RM Viani, V Alagappan, MN Pangalos… - The Lancet …, 2022 - thelancet.com
Background Early intramuscular administration of SARS-CoV-2-neutralising monoclonal
antibody combination, tixagevimab–cilgavimab, to non-hospitalised adults with mild to …